HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Noble, S. Articles by Dimmock, N. J. Search for Related Content PubMed PubMed Citation Articles by Noble, S. Articles by Dimmock, N. J. Agricola Articles by Noble, S. Articles by Dimmock, N. J.

Defective interfering type A equine influenza virus (H3N8) protects mice from morbidity and mortality caused by homologous and heterologous subtypes of influenza A virus

S. Noble

Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, U.K.

Intranasal administration of defective interfering A/equine/Newmarket/7339/79 (H3N8) influenza virus (DI EQV) protected mice from otherwise lethal intranasal infection with homologous virus (EQV) or with the heterologous subtypes A/WSN (H1N1) or A/PR/8/34 (H1N1). Such protected mice showed little or no sign of clinical disease. Disease with only low mortality resulting from a ‘low’ dose of WSN was completely prevented with a 100-fold lower dose of DI EQV (4 haemagglutinating units/ml or 12 ng virus/mouse), indicating that there was a roughly proportional relationship between the protective dose of DI virus and the infecting inoculum. DI EQV-protected mice continued to gain weight at the normal rate, whereas those treated with inactivated DI EQV ceased putting on weight for about 7 days and were still underweight nearly 3 weeks later. Unlike DI WSN, DI EQV inhibited multiplication of infectious WSN in the lungs by 20 to 60-fold. Intranasal DI EQV on its own gave little protection to mice challenged 24 days later with EQV suggesting that it was only weakly immunogenic. DI EQV afforded significant protection when given up to 5 days before live virus challenge indicating that the DI genome remained active in the respiratory tract for this period of time.

Present address: Institute for Molecular Virology, University of Wisconsin-Madison, Madison, Wisconsin 53706-1596, U.S.A.

Received 27 May 1994; accepted 23 August 1994.

This article has been cited by other articles:

				N. J. Dimmock, E. W. Rainsford, P. D. Scott, and A. C. Marriott Influenza Virus Protecting RNA: an Effective Prophylactic and Therapeutic Antiviral J. Virol., September 1, 2008; 82(17): 8570 - 8578. [Abstract] [Full Text] [PDF]

				N. J. Dimmock and A. C. Marriott In vivo antiviral activity: defective interfering virus protects better against virulent Influenza A virus than avirulent virus. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1259 - 1265. [Abstract] [Full Text] [PDF]